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MicroRNAs are well suited to regulate tumor metas-
tasis because of their capacity to coordinately
repress numerous target genes, thereby potentially
enabling their intervention at multiple steps of the
invasion-metastasis cascade. We identify a micro-
RNA exemplifying these attributes, miR-31, whose
expression correlates inversely with metastasis in
human breast cancer patients. Overexpression of
miR-31 in otherwise-aggressive breast tumor cells
suppresses metastasis. We deploy a stable micro-
RNA sponge strategy to inhibit miR-31 in vivo; this
allows otherwise-nonaggressive breast cancer cells
to metastasize. These phenotypes do not involve
confounding influences on primary tumor develop-
ment and are specifically attributable to miR-31-
mediated inhibition of several steps of metastasis,
including local invasion, extravasation or initial
survival at a distant site, and metastatic colonization.
Such pleiotropy is achieved via coordinate repres-
sion of a cohort of metastasis-promoting genes,
including RhoA. Indeed, RhoA re-expression partially
reverses miR-31-imposed metastasis suppression.
These findings indicate that miR-31 uses multiple
mechanisms to oppose metastasis.
For a video summary of this article, see the Paper-
Flick file available with the online Supplemental Data.
INTRODUCTION
Metastases account for 90% of human cancer deaths (Gupta and
Massague´, 2006), yet our understanding of the molecular circuitry
that governs metastatic dissemination remains fragmentary. The1032 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.invasion-metastasis cascade, which leads to these growths, is
a complex, multistep process involving the escape of neoplastic
cells from a primary tumor (local invasion), intravasation into the
systemic circulation, survival during transit through the vascula-
ture, extravasation into the parenchyma of distant tissues, the
establishment of micrometastases, and ultimately the outgrowth
of macroscopic secondary tumors (colonization) (Fidler, 2003).
MicroRNAs (miRNAs) constitute an evolutionarily conserved
class of pleiotropically acting small RNAs that suppress gene
expression posttranscriptionally via sequence-specific interac-
tions with the 30 untranslated regions (UTRs) of cognate mRNA
targets (Bartel, 2009). In mammalian cells, miRNAs effect gene
silencing via both translational inhibition and mRNA degradation;
an individual miRNA is capable of regulating dozens of distinct
mRNAs, and together the >650 human miRNAs are believed to
modulate more than one-third of the mRNA species encoded
in the genome (Bartel, 2009).
A central role for miRNAs in the establishment and progression
of human tumors has begun to emerge. More than 50% of
miRNA-encoding loci reside in chromosomal regions altered
during tumorigenesis (Calin et al., 2004), and expression profiling
reveals characteristic miRNA signatures for many tumor types—
including breast neoplasias—that predict disease status and
clinical outcome (Calin and Croce, 2006). In addition, miRNAs
have been identified that function as classical oncogenes or
tumor suppressor genes (Ventura and Jacks, 2009), as well as
a limited number that act at late stages of tumor progression
(Ma et al., 2007; Tavazoie et al., 2008; Huang et al., 2008; Asan-
gani et al., 2008; Zhu et al., 2008; Lujambio et al., 2008).
The extent to which miRNAs specifically affect metastasis
remains unclear, because all the miRNAs reported to affect
metastasis also exert potentially confounding influences on
primary tumor development, apoptosis, and/or cell proliferation
(Voorhoeve et al., 2006; Sathyan et al., 2007; Ma et al., 2007;
Si et al., 2007; Tavazoie et al., 2008; Kondo et al., 2008; Lujambio
et al., 2008). Moreover, a role for miRNAs in steps of the invasion-
metastasis cascade subsequent to local invasion has not been
described.
The pleiotropic nature of gene regulation exhibited by miRNAs
led us to hypothesize that certain miRNAs might be endowed
with a capacity to function as crucial modulators of tumor metas-
tasis. Here, we identify an antimetastatic human miRNA, miR-31,
that acts at multiple steps of the invasion-metastasis cascade
via repression of a cohort of prometastatic targets.
RESULTS
miR-31 Expression Is Specifically Attenuated
in Metastatic Breast Cancer Cell Lines
To identify miRNAs that might regulate breast cancer metas-
tasis, we selected 10 cancer-associated miRNAs for further
characterization because of their concordant identification
among expression profiling studies of clinical breast tumors
(Iorio et al., 2005; Volinia et al., 2006), global analysis of miRNA
copy-number variation in human breast carcinomas (Zhang
et al., 2006), and localization of miRNA loci to cancer-relevant
sites of chromosomal aberration (Table S1 available online; Calin
et al., 2004). These studies did not stratify patients based on
metastasis status.
Expression of the 10 candidate miRNAs was assayed in 15
human and mouse mammary cell lines, which included normal
epithelial cells, tumorigenic but nonmetastatic cells, and meta-
static tumor cells (Table S2). The levels of a single miRNA, miR-
31, were specifically attenuated in aggressive human breast
cancer cells when compared to primary normal human mammary
epithelial cells (HMECs). Although nonmetastatic tumor cells
(HMLER, MCF7-Ras, and SUM-149) exhibited 4-fold reduced
miR-31, expression of this miRNA in metastatic SUM-159 and
MDA-MB-231 cells was diminished by >100-fold (Figure 1A).
Relative to its expression in normal murine mammary gland
(NMuMG) cells, miR-31 levels in sublines derived from a single
murine mammary tumor reflected their capacities to metasta-
size: miR-31 was reduced by 2-fold in metastatic D2.1 and
D2A1 cells, but not in nonaggressive D2.OR cells (Figure 1B).
miR-31 levels were also inversely proportional to metastatic
ability in four mouse mammary carcinoma sublines derived
from a single spontaneously arising tumor: although miR-31
levels in nonaggressive 67NR cells were similar to those in
NMuMG, miR-31 expression was progressively diminished
upon acquisition of the capacity to invade locally (168FARN),
to form micrometastases (4TO7), and to yield macroscopic
metastases (4T1) (Figure 1B). Thus, miR-31 levels are specifically
attenuated in aggressive breast cancer cells.
miR-31 expression was heterogeneous in 4T1 cell primary
mammary tumors; of note, the proportion of cells expressing
miR-31 was 10-fold reduced in lung metastases relative to the
fraction of miR-31-positive cells in the primary tumors from
which they were derived (Figure 1C). Also, 5-fold fewer cells
located near the invasive front of 4T1 cell mammary tumors ex-
pressed miR-31, compared to cells in the interior of these tumors
(Figure 1D). These data raise the possibility that selective pres-
sures diminish the prevalence of miR-31-expressing cells within
the pool of successfully metastasizing cells during the course of
metastatic progression.miR-31 Expression Suppresses Metastasis-Relevant
Traits In Vitro
Given these inverse correlations between miR-31 levels and
malignant phenotypes, we assessed the potential for antimeta-
static roles for miR-31. Thus, we stably expressed miR-31 in
metastatic MDA-MB-231 human breast cancer cells (‘‘231
cells’’). This overexpression resulted in miR-31 levels compa-
rable to those in HMECs (Figure S1A).
Ectopic miR-31 did not affect proliferation in vitro, but did
reduce invasion by 20-fold and motility by 10-fold (Figure 2A;
Figures S1B and S1C). These effects were specifically attribut-
able to the biological activities of miR-31, as indicated by the fact
that equivalent overexpression of a control miRNA, miR-145,
failed to influence invasion or motility (Figure 2A and data not
shown). Also, miR-31-expressing cells exhibited 60% dimin-
ished resistance to anoikis-mediated cell death (Figure 2B).
These defects could not be ascribed to toxicity resulting from
ectopic miR-31 (Figure S1D). The consequences of miR-31
expression were not unique to 231 cells: miR-31 reduced inva-
sion, motility, and anoikis resistance, yet did not affect prolifera-
tion, in aggressive SUM-159 human breast cancer cells
(Figure S2). Hence, miR-31 impairs in vitro surrogates of meta-
static ability.
miR-31 Expression Suppresses Metastasis In Vivo
Because of its effects on in vitro traits associated with high-
grade malignancy, we asked whether ectopic miR-31 could
inhibit metastasis in otherwise-aggressive cells. Thus, 231 cells
expressing miR-31 were injected into the orthotopic site—the
mammary fat pad—of mice. Unexpectedly, miR-31 enhanced
primary tumor growth by 1.5-fold and correspondingly increased
cell proliferation (Figure 2C; Figure S3A). Control 231 cell primary
tumors displayed evidence of local invasion; however, miR-31-
expressing tumors were well encapsulated and noninvasive
(Figures 2D and 2E). These changes were not accompanied by
altered neovascularization (Figure S3B).
Despite their ability to generate larger primary tumors, 231
cells expressing miR-31 were strikingly impaired in their capacity
to seed lung metastases. miR-31-expressing cells formed 95%
fewer lesions than did controls 62 days after implantation
(Figure 2F). Thus, miR-31 suppresses metastasis from an ortho-
topic site, ostensibly due, at least in part, to its ability to impede
local invasion.
We addressed the possibility that miR-31’s impact on these
parameters was attributable to clonal variation in our 231 cells
by expressing miR-31 in a single-cell-derived population iso-
lated from the parental 231 cells (Figure S4A; Minn et al.,
2005). As before, when injected orthotopically, miR-31-express-
ing cells formed large, well-encapsulated primary tumors and
also reduced lung metastasis by 5-fold (Figures S4B–S4D).
Orthotopic injection of SUM-159 cells expressing miR-31 further
corroborated our earlier findings: miR-31 enhanced primary
tumor growth, yet miR-31-expressing tumors were better
confined than control tumors (Figure S5). These observations
indicated that the ability of miR-31-expressing cells to form
larger, less invasive primary tumors, as well as to seed fewer
metastases, is a specific consequence of the biological activities
of miR-31.Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc. 1033
Figure 1. miR-31 Levels Correlate Inversely with Metastatic Ability in Breast Cell Lines
(A) RT-PCR for miR-31 in seven human breast cell lines. 5S rRNA was a loading control. NTC, no template control. n = 3.
(B) miR-31 RT-PCR in eight murine mammary cell lines. 5S rRNA was a loading control. n = 3.
(C) In situ hybridization for miR-31 (green) in animal-matched 4T1 cell primary mammary tumors and lung metastases; DAPI counterstain (blue). n = 4.
(D) Hematoxylin and eosin (H&E) stain of a 4T1 cell primary mammary tumor (top); box: invasive front. miR-31 in situ hybridization in 4T1 cells located near the
invasive front or the interior of the primary tumors (bottom). n = 3.
Data are presented as mean ± SEM.We determined whether miR-31’s impact on metastasis was
also attributable to effects on later steps of the invasion-metas-
tasis cascade, independent of its influence on local invasion.
Thus, we injected miR-31-expressing 231 cells directly into the
circulation of mice, thereby circumventing the initial steps of
local invasion and intravasation. After 1 day, miR-31-expressing
cells were 4-fold impaired in their ability to persist in the lungs
(Figure 2G). This difference was not a consequence of an inability
of miR-31-expressing cells to become lodged initially in the lung
microvasculature, as shown by the fact that equal numbers of
miR-31-expressing and control cells were detected in the lungs
10 min and 2 hr after injection (Figure 2G; Figure S6A). These
observations suggested that miR-31 regulates early postintrava-1034 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.sation events, such as intraluminal viability, extravasation, and/
or initial survival in the lung parenchyma.
Three months after tail vein injection, miR-31-expressing 231
cells generated 40-fold fewer lung metastases than did controls
(Figure 2G). We also observed a dramatic effect on the size of
eventually formed lesions: after 3 months, miR-31-expressing
cells generated only small micrometastases although control
cells formed macroscopic metastases; this occurred despite
the fact that miR-31-expressing and control cells established
comparably sized micrometastases 1 month after injection
(Figure 2G; Figure S6B). Such effects on lesion size implied
that miR-31 affects metastatic colonization in addition to its influ-
ences on local invasion and early postintravasation events.
Inhibition of miR-31 Promotes Metastasis-Relevant
Traits In Vitro
The preceding observations demonstrated that miR-31 expres-
sion deprives metastatic cells of attributes associated with
high-grade malignancy. We next asked whether miR-31 also
prevents the acquisition of aggressive traits by otherwise-non-
metastatic human breast cancer cells. To do so, we transiently
inhibited miR-31 in noninvasive MCF7-Ras cells with either anti-
sense oligonucleotides or miRNA sponges. The latter are
expression constructs that carry miRNA recognition motifs in
their 30 UTR that bind and thus titer miRNAs (Ebert et al.,
2007). Both approaches inhibited miR-31 function by >4.5-fold
(Figure S7A). Suppression of miR-31 enhanced invasion by
20-fold and motility by 5-fold, but cell viability was unaffected
by either inhibitor (Figure 3A; Figure S7B).
Techniques for stable miRNA inhibition have been unavailable
(Kru¨tzfeldt et al., 2006). To address this problem, we modified
elements derived from the transiently expressed miRNA
sponges, cloned them into a retroviral vector, and created
MCF7-Ras cells that stably express the modified miRNA
sponges. The miR-31 sponge reduced miR-31 function by
2.5-fold, but did not affect the activity of other known antimeta-
static miRNAs (Figures S8A and S8B). The relatively modest
suppression of miR-31 conferred by stable sponge expression
elicited strong responses: invasion was enhanced by 12-fold,
motility by 8-fold, and anoikis resistance by 2.5-fold (Figure 3B;
Figure S8C). The miR-31 sponge failed to alter in vitro prolifera-
tion (Figure S8D).
When stably expressed in immortalized HMECs or tumori-
genic but nonmetastatic SUM-149 human breast cancer cells,
the miR-31 sponge elicited increased invasion, motility, and
anoikis resistance without affecting proliferation (Figure S9 and
data not shown). Collectively, these data indicated that sus-
tained miR-31 activity is necessary to prevent the acquisition
of aggressive traits by both tumor cells and untransformed
breast epithelial cells.
Inhibition of miR-31 Promotes Metastasis In Vivo
We exploited our ability to stably inhibit miRNAs in order to assess
whether miR-31 activity is required to prevent metastasis in vivo.
To do so, otherwise-nonmetastatic MCF7-Ras cells stably ex-
pressing the miR-31 sponge were orthotopically implanted into
mice. Inhibition of miR-31 failed to alter in vivo proliferation and
primary tumor growth (Figure 3C; Figure S10A). Primary tumors
derived from miR-31 sponge-expressing cells were poorly
encapsulated and locally invasive, whereas control MCF7-Ras
tumors appeared well confined and noninvasive (Figures 3D
and 3E). Again, neovascularization did not differ (Figure S10B).
Strikingly, miR-31 sponge-expressing MCF7-Ras cells metas-
tasized to the lungs in significant numbers, whereas control
tumor-bearing host lungs were largely devoid of tumor cells;
cells with impaired miR-31 activity formed 10-fold more lesions
than did controls (Figure 3F). Hence, continuous miR-31 function
is required to prevent metastasis from an orthotopic site.
We asked whether loss of miR-31 activity also promoted
metastasis by intervening at steps of the invasion-metastasis
cascade subsequent to local invasion. Thus, we intravenously in-
jected mice with miR-31 sponge-expressing MCF7-Ras cells.Within 1 day, miR-31 inhibition enhanced cell number in the
lungs by 6-fold; similarly, at later times after injection, miR-31
sponge-expressing cells were 10-fold more prevalent in the
lungs than were controls (Figure 3G). The differing metastatic
abilities of control and miR-31 sponge-expressing cells did not
arise because of failure of control cells to become lodged initially
in the lung vasculature, as shown by the fact that equal numbers
of cells from each cohort were present 10 min after injection
(Figure 3G; Figure S11).
Suppression of miR-31 also affected lesion size 4 months after
tail vein injection: whereas control cells formed only small micro-
metastases, miR-31 sponge-expressing cells produced macro-
scopic metastases (Figure 3G). Together, these data extended
and reinforced our ectopic expression studies by demonstrating
that miR-31 affects local invasion, early postintravasation
events, and metastatic colonization.
miR-31 Directly Regulates a Cohort of Prometastatic
Genes
miR-31’s ability to impede multiple steps of the invasion-metas-
tasis cascade might derive from its ability to pleiotropically regu-
late genes involved in diverse aspects of metastatic dissemina-
tion. To identify effectors of miR-31, we used two algorithms that
predict the mRNA targets of a miRNA—PicTar (Krek et al., 2005)
and TargetScan (Grimson et al., 2007). Based on the representa-
tion of miR-31 sites in their 30 UTRs, >200 mRNAs were predicted
to be regulated by miR-31. Gene ontology (Ashburner et al.,
2000) revealed that these targets included a disproportionately
large number of genes encoding proteins with roles in motility-
related processes, such as cell adhesion, cytoskeletal remodel-
ing, and cell polarity (data not shown).
Guided by this gene ontology analysis, we cloned the 30 UTRs
of 16 putative miR-31 targets from these overrepresented cate-
gories, including several implicated in tumor invasion (Sahai and
Marshall, 2002; McClatchey, 2003), into a luciferase construct.
Reporter assays with miR-31-expressing 231 cells revealed
that miR-31 repressed six of the UTRs: frizzled3 (Fzd3), integrin
a5 (ITGA5), myosin phosphatase-Rho interacting protein
(M-RIP), matrix metallopeptidase 16 (MMP16), radixin (RDX),
and RhoA (Figure 4A). Mutation of the putative miR-31 site(s) in
these six 30 UTRs (Table S3) abrogated responsiveness to
miR-31 (Figure 4B). In the case of RhoA, whose UTR contains
two miR-31 sites separated by 152 nucleotides, mutation of
either motif abolished miR-31 responsiveness (Figure 4B), sug-
gesting functional interaction between the sites (Grimson et al.,
2007).
Endogenous Fzd3, ITGA5, MMP16, RDX, and RhoA protein
levels were assayed in miR-31-expressing 231 cells. miR-31
repressed the levels of these proteins by 40%–60%
(Figure 4C). miR-31’s effects on levels of the M-RIP protein could
not be evaluated because of the lack of appropriate antibodies.
Also, miR-31 reduced the endogenous mRNA levels of these six
targets by 2-fold in SUM-159 cells, as well as Fzd3, ITGA5,
MMP16, RDX, and RhoA mRNA levels in 231 cells (Figure 4D).
miR-31 did not affect CXCL12 mRNA levels—a computationally
predicted miR-31 target found not to be regulated by this
miRNA—in either cell type (Figures 4A and 4D). These data indi-
cated that miR-31 directly regulates endogenous Fzd3, ITGA5,Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc. 1035
Figure 2. miR-31 Expression Inhibits Metastasis
(A) Invasion and motility assays after transfection of MDA-MB-231 (231) cells with the indicated constructs. n = 3.
(B) Anoikis assays with 231 cells infected as indicated. n = 3.
(C) Primary tumor growth upon orthotopic injection of 1.0 3 106 GFP-labeled 231 cells infected as indicated. The experiment was terminated after 13 weeks
because of primary tumor burden. n = 5 per group per time point.
(D) H&E stain of 231 primary tumors 62 days after orthotopic injection.
(E) H&E stain of tissue adjacent to the indicated 231 primary mammary tumors 62 days after injection. Arrows: disseminated tumor cells in normal fat (a, b), muscle
(c, d), and subcutis (e, f).
(F) Images of murine lungs to visualize GFP-labeled 231 cells 62 days after orthotopic implantation (left). H&E stain of lungs from animals bearing the indicated
tumors (right); arrows indicate metastatic foci. n = 5.1036 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.
M-RIP, MMP16, RDX, and RhoA expression in human breast
cancer cells.
We determined whether concomitant repression of Fzd3,
ITGA5, M-RIP, MMP16, RDX, and RhoA correlated with disease
progression in clinical breast cancers by examining expression
profiling data from 295 primary breast tumors (Table S4; van
de Vijver et al., 2002). To do so, we constructed a miR-31 target
signature based on coordinate differential expression of these
six genes. Within this cohort, high expression of the miR-31
target signature was associated with metastasis, as well as
poor survival, relative to signature-negative tumors; 5-year
survival among patients negative for the target signature was
90%, whereas >35% of target signature-positive patients suc-
cumbed to their disease over this interval (Figures 5A and 5B).
Thus, coordinate repression of Fzd3, ITGA5, M-RIP, MMP16,
RDX, and RhoA correlated with more favorable outcome in clin-
ical breast tumors.
To assess the functional contributions of these miR-31 targets
to aggressive phenotypes, we first examined whether their inhi-
bition affected the invasion or motility of 231 cells. Transfection
with siRNAs potently reduced target protein levels without
affecting cell viability (Figures S12A and S12B). siRNAs targeting
Fzd3, ITGA5, RDX, or RhoA reduced invasion and motility,
whereas siRNAs against M-RIP or MMP16 failed to affect these
traits (Figure 5C; Figure S12C).
We asked whether inhibition of these effectors compromised
resistance to anoikis. siRNAs against ITGA5, RDX, or RhoA
sensitized 231 cells to anoikis; in contrast, siRNAs targeting
Fzd3, M-RIP, or MMP16 had no effect on anoikis resistance
(Figure 5D). Hence, suppression of Fzd3, ITGA5, RDX, or RhoA
impaired metastasis-relevant traits in vitro.
Re-expression of Fzd3, ITGA5, RDX, and RhoA Reverses
miR-31-Dependent Metastasis-Relevant Phenotypes
In Vitro
To determine whether in vitro phenotypes associated with
miR-31 expression could be reversed via restoration of Fzd3,
ITGA5, M-RIP, MMP16, RDX, or RhoA levels, we transfected
miR-31-expressing 231 cells with individual expression con-
structs rendered miRNA insensitive by deletion of their 30 UTRs;
this was not cytotoxic (Figures S13A and S13B and data not
shown). In miR-31-expressing cells, Fzd3, ITGA5, RDX, or
RhoA reversed, at least partially, miR-31-imposed invasion and
motility defects; in contrast, M-RIP or MMP16 had no effect on
these traits (Figure 5E; Figure S13C). Surprisingly, re-expression
of RDX or RhoA completely rescued miR-31-mediated invasion
and motility defects. Expression of the six targets failed to
enhance the invasion or motility of control 231 cells (Figure 5E;
Figure S13C).
We evaluated whether re-expression of any of the six targets
rescued miR-31’s effects on anoikis. ITGA5, RDX, or RhoA
reversed, at least in part, anoikis susceptibility resulting from
ectopic miR-31; in contrast, Fzd3, M-RIP, or MMP16 failed to
affect this trait (Figure 5F). In fact, ITGA5 or RhoA completelyrescued miR-31-dependent anoikis phenotypes. The six targets
did not enhance anoikis resistance in control 231 cells
(Figure 5F). Hence, Fzd3, ITGA5, RDX, and RhoA are functionally
relevant effectors of miR-31 for conferring malignant traits
in vitro.
Re-expression of RhoA Partially Reverses
miR-31-Imposed Metastasis Defects In Vivo
RhoA afforded the most pronounced reversal of miR-31-medi-
ated phenotypes. Therefore, we stably re-expressed miRNA-
resistant RhoA in 231 cells that already had been infected with
either miR-31 or control vector (Figures S14A and S14B). RhoA
did not affect proliferation in vitro, but did abrogate miR-31-
imposed invasion, motility, and anoikis resistance defects
(Figures S14C–S14F).
To ascertain whether restored RhoA levels reversed in vivo
metastasis phenotypes ascribable to miR-31, we orthotopically
injected mice with 231 cells expressing combinations of miR-
31, RhoA, and control vectors. As observed previously, miR-31
enhanced primary tumor growth (Figure 6A). RhoA initially
augmented primary tumor growth in the presence of ectopic
miR-31, but failed to do so in control 231 cells (Figure 6A). In
consonance with our earlier findings, control 231 primary tumors
were locally invasive and miR-31-expressing tumors were nonin-
vasive (Figures 6B and 6C). In control 231 cells, ectopic RhoA
failed to exacerbate the extent of local invasion; in contrast,
RhoA abolished the previously encapsulated appearance of
miR-31-expressing tumors and enabled invasion into
surrounding normal tissue (Figures 6B and 6C).
Re-expression of RhoA restored lung metastasis in miR-31-
expressing 231 cells to 75% of control cell levels, although
RhoA failed to enhance metastasis in control 231 cells
(Figure 6D). Thus, re-expression of RhoA partially, yet robustly,
reverses metastasis suppression imposed by miR-31. The
observed magnitude of rescue is surprising, because RhoA is
only one member of a larger cohort of metastasis-relevant genes
repressed by miR-31.
By intravenously injecting mice with 231 cells expressing
miR-31 and/or RhoA, we gauged whether RhoA-mediated
reversal of miR-31-imposed metastasis defects was solely
attributable to effects on local invasion. Although expression of
miR-31 and/or RhoA failed to affect the initial lodging of tumor
cells in the lung vasculature, the number of cells that persisted
in the lungs differed within one day of injection (Figure 6E;
Figure S15). As before, miR-31 inhibited both the number of
metastases formed and their eventual size (Figure 6E). Although
expression of RhoA in control 231 cells failed to enhance metas-
tasis, RhoA restored the number of lung metastases to 60% of
control cell levels in miR-31-expressing cells; however, RhoA
did not facilitate the formation of macroscopic metastases in
cells with ectopic miR-31 (Figure 6E).
Together, these data indicated that miR-31’s ability to inhibit
metastasis is attributable, in significant part, to its capacity to
inhibit RhoA. miR-31-mediated repression of RhoA affects(G) Images of murine lungs to detect GFP-labeled 231 cells 88 days after tail vein injection (left). H&E stain of lungs (right); arrows indicate metastatic foci.
Asterisks: p > 0.66. n = 5, except for 10 min and 2 hr (n = 4).
Data are presented as mean ± SEM.Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc. 1037
Figure 3. Inhibition of miR-31 Promotes Metastasis
(A) Invasion and motility assays with MCF7-Ras cells transfected with the indicated transient miR-31 inhibitors. n = 3.
(B) Anoikis assays with MCF7-Ras cells stably expressing the indicated sponge. n = 3.1038 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.
both local invasion and early postintravasation events. However,
these data also implied that the full spectrum of miR-31’s effects
on metastasis are elicited only via the coordinate repression of
multiple targets, because suppression of RhoA alone could not
explain the complete impact of miR-31 on the number of metas-
tases formed or its effects on metastatic colonization.
Figure 4. miR-31 Directly Regulates a Cohort of Prometastatic Genes
(A) Luciferase activity in 231 cells infected with miR-31 or control vector after transfection of the indicated 30 UTR-driven reporter constructs. n = 3.
(B) Luciferase activity in the indicated 231 cells upon transfection of miR-31 site mutant 30 UTR-driven reporter constructs. wt: wild-type; site 1: the miR-31 motif
at nt 145–151 of the RhoA 30 UTR; site 2: the motif spanning nt 303–309. Asterisks: p > 0.80 relative to mutant-UTR + vector controls. n = 3.
(C) Immunoblots for endogenous Fzd3, ITGA5, MMP16, RDX, and RhoA in the indicated 231 cells. b-actin was a loading control. Repression: protein levels in
miR-31-expressing cells relative to vector controls.
(D) RT-PCR for endogenous CXCL12, Fzd3, ITGA5, M-RIP, MMP16, RDX, and RhoA. GAPDH was a loading control. Asterisks: p < 0.03 relative to vector controls.
n = 3.
Data are presented as mean ± SEM.(C) Primary tumor growth upon orthotopic implantation of 5.03 105 GFP-labeled MCF7-Ras cells infected as indicated. The experiment was terminated after 16
weeks because of primary tumor burden. n = 5 per group per time point.
(D) H&E stain of MCF7-Ras primary tumors 47 days after orthotopic injection. Arrows indicate regions of poor encapsulation.
(E)H&E stainof tissueadjacent to the indicatedMCF7-Rasprimary tumors47days postinjection. Arrows: disseminated tumor cells innormal fat (a, c)and muscle (b, d).
(F) Images of murine lungs to visualize GFP-labeled MCF7-Ras cells 113 days after orthotopic injection (left). H&E stain of lungs from animals bearing the indicated
tumors (middle); arrows indicate metastatic foci. n = 5.
(G) Images of murine lungs to detect GFP-labeled MCF7-Ras cells 122 days after tail vein injection (left). H&E stain of lungs (middle); arrow indicates metastasis. n = 4,
except for 1 day (n = 3).
Data are presented as mean ± SEM.Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc. 1039
Figure 5. Repression of Fzd3, ITGA5, RDX, and RhoA Underlies miR-31-Dependent Phenotypes In Vitro
(A) Kaplan-Meier curves for 295 human primary breast tumors depicting metastasis-free survival, stratified based on expression of the 6-gene miR-31 target
signature. p value based on a logrank test.
(B) Kaplan-Meier 5-year survival curves for 295 breast cancer patients, stratified based on miR-31 target signature expression in their primary tumors. p value
based on a logrank test.
(C) Invasion assays with miR-31-expressing or control 231 cells transfected as indicated. Asterisks: p > 0.19 relative to vector + siControl cells. n = 3.
(D) Anoikis assays with 231 cells transfected with the indicated siRNAs. Asterisks: p > 0.80 relative to vector + siControl cells. n = 3.
(E) Invasion assays with the indicated 231 cells transfected with miRNA-resistant expression constructs. Asterisks: p > 0.61 relative to miR-31 + mock cells. n = 3.
(F) Anoikis assays with the indicated 231 cells transfected as noted. Asterisks: p > 0.11 relative to miR-31 + mock cells. n = 3.
Data are presented as mean ± SEM.miR-31 Expression Correlates Inversely withMetastasis
in Human Breast Tumors
Because established cell lines and xenograft studies cannot fully
recapitulate clinical malignancy, we extended our analyses by
assaying miR-31 expression in specimens from 56 human breast
cancer patients (Table S5; median follow-up = 59 months). Rela-
tive to grade-matched estrogen receptor (ER)+ tumors, which are
associated with more favorable disease outcome (Sørlie et al.,
2001), basal-like tumors exhibited 40% reduced miR-31; no1040 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.difference in miR-31 levels was observed between ER+ and
HER2+ tumors (Figure S16).
When these 56 tumors were stratified based on clinical
progression, we found that miR-31 expression was diminished
in primary tumors that subsequently metastasized, when
compared to normal breast tissue and primary tumors that did
not recur; moreover, low miR-31 levels correlated strongly with
reduced distant disease-free survival relative to tumors with
high miR-31 (Figures 7A and 7B). Similarly, within this cohort of
tumors, high RhoA expression was associated with an increased
incidence of distant metastasis (Figure S17).
The association of low miR-31 levels with metastasis persisted
independent of both tumor grade and molecular subtype
(Figure S18). Such grade and subtype independence is quite
surprising, because clinically utilized prognostic markers for
breast cancer largely correlate with these parameters; further-
more, currently available markers do not identify a worse-prog-
nosis group within the more aggressive basal-like or HER2+
subtypes (Desmedt et al., 2008). Thus, miR-31 may represent
a marker for metastasis in a variety of breast cancer subtypes;
however, its utility as a prognostic indicator will depend on
extension of these initial observations.
We next assessed the heterogeneity of miR-31 expression in
human primary breast tumors, as well as distant metastases
arising in the same patients. miR-31 was expressed in 65% of
the cells in these primary tumors; however, miR-31 was detected
in only 12%–30% of cells in patient-matched distant metastases
(Figure 7C). These data raise the possibility that selective pres-
sures operating over the course of breast cancer progression
diminish the representation of miR-31-expressing cells within
the population of successfully metastasizing cells.
Finally, we asked whether expression of ITGA5, RDX, and
RhoA was also heterogeneous in primary human breast tumors.
RDX and RhoA were expressed in 60%–75% of cells in the
primary tumors examined, whereas ITGA5 was detected in
>80% of cells (Figure 7D). Distant metastases were more homo-
geneous for the expression of RDX and RhoA than the primary
tumors from which they were derived, as indicated by the fact
that >90% of cells in the metastases expressed RDX and
RhoA (Figure 7D). Similarly, >90% of cells in the metastases ex-
pressed ITGA5; however, the widespread ITGA5 expression
observed in the patient-matched primary tumors complicates
interpretation of its expression in distant metastases (Figure 7D).
DISCUSSION
miRNAs can modulate a wide variety of biological processes. In
the present report, we demonstrate that a single human miRNA,
miR-31, is endowed with the ability to concomitantly repress
multiple prometastatic targets and to thereby inhibit several
distinct steps of the invasion-metastasis cascade. Moreover,
miR-31 levels correlate inversely with metastatic recurrence in
a cohort of human breast tumors, a preliminary association
that appears to persist independent of both tumor grade and
subtype.
Genome-wide studies have described miR-31 downregulation
or deletion of the miR-31 genomic locus in human breast cancers
(Calin et al., 2004; Zhang et al., 2006; Yan et al., 2008). Expres-
sion profiling of clinical breast tumors revealed reduced miR-
31 in luminal B (relative to luminal A), basal-like, and HER2+
tumors (Mattie et al., 2006; Blenkiron et al., 2007)—patterns of
reduction that correlate with aggressive disease (Sørlie et al.,
2001). In contrast, another profiling study found elevated miR-
31 in human breast tumors (Volinia et al., 2006). None of these
studies stratified patients by metastasis status.
A limited number of miRNAs with prometastic (miR-10b, -21,
and -373/520c) or antimetastatic (miR-34b/c, -126, -148a, -206,and -335) functions have been identified. However, the contribu-
tions of miR-10b, miR-21, and miR-373/520c specifically to
metastasis promotion are not easily discerned because of their
mitogenic and/or antiapoptotic roles (Voorhoeve et al., 2006;
Ma et al., 2007; Si et al., 2007). Similarly, the antimetastatic
miRNAs miR-34b/c, miR-126, and miR-148a impair primary
tumor growth (Lujambio et al., 2008; Tavazoie et al., 2008),
whereas miR-206 and miR-335 inhibit proliferation or promote
apoptosis (Sathyan et al., 2007; Kondo et al., 2008), again
obscuring their precise roles in metastasis.
In contrast, miR-31 obstructs metastasis without exerting
confounding influences on primary tumor development. As
such, mir-31 might aptly be categorized as a ‘‘metastasis
suppressor gene’’ (Steeg, 2003). This unique aspect of miR-31
function, among others, raises questions regarding the still-
uncharacterized role of this miRNA in normal cell and organismic
physiology. Of significance, loss of miR-31 activity enhances
invasiveness, motility, and anoikis resistance in untransformed
human mammary epithelial cells. Hence, inactivation of miR-31
in normal epithelium may facilitate dissemination prior to trans-
formation to a fully neoplastic state. This suggests one putative
mechanism by which the invasion-metastasis cascade could
be initiated very early during the course of tumor progression,
a phenomenon that has recently been observed in clinical breast
tumors (Hu¨semann et al., 2008).
Given the capacity of miR-31 to enhance primary tumor
growth, an oncogenic role for this miRNA (mechanistically inde-
pendent of its metastasis-suppressive functions) cannot be
formally excluded. Such duality of action is not unprecedented
(Massague´, 2008) and is consistent with notions that metastasis-
and tumorigenesis-enabling attributes can be biologically dis-
tinct and acquired via independent selective pressures during
malignant progression.
Previous studies have described effects of specific miRNAs on
an early stage of the invasion-metastasis cascade—local inva-
sion. The present work demonstrates that miRNAs can also influ-
ence later steps of metastasis and that an individual miRNA can
intervene at multiple distinct stages of the invasion-metastasis
cascade. miR-31 regulates the local invasion of primary
mammary tumors, as well as intraluminal survival, extravasation,
and/or initial viability in a foreign microenvironment. miR-31 also
suppresses colonization—the final and rate-limiting step of
metastasis (Fidler, 2003). miR-31-imposed suppression of
RhoA partially explains the effects of this miRNA on local inva-
sion and early postintravasation events; however, the mecha-
nisms by which miR-31 suppresses metastatic colonization
remain unresolved.
The levels of several functionally relevant effectors of miR-31
correlate with disease progression in human tumors. RhoA
expression, for example, is elevated in aggressive breast neopla-
sias (Sahai and Marshall, 2002). Similar associations have been
described in human tumors for ITGA5 (Sanchez-Carbayo et al.,
2006) and the RDX family (McClatchey, 2003).
Re-expression of several individual miR-31 targets largely
reversed miR-31-imposed defects in vitro. This may indicate
that certain miR-31 effectors activate one another; however,
ectopic ITGA5, RDX, or RhoA did not induce the expression of
other miR-31 targets (data not shown). Alternatively, availableCell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc. 1041
Figure 6. Re-expression of RhoA Partially Reverses miR-31-Imposed Metastasis Defects In Vivo
(A) Primary tumor growth upon orthotopic injection of 5.03 105 GFP-labeled 231 cells. The experiment was terminated after 11 weeks because of primary tumor
burden. Asterisks: p < 0.02. n = 5 per group per time point.
(B) H&E stain of 231 primary tumors 60 days after orthotopic injection.1042 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.
Figure 7. miR-31 Levels Correlate Inversely with Metastasis in Human Breast Tumors
(A) miR-31 RT-PCR in 54 primary breast tumors. Normal: tissue from nondiseased individuals; metastasis-positive and -free: tumors of the indicated distant
metastasis outcome. 5S rRNA was a loading control. n = 4 (normal); n = 14 (metastasis-positive); n = 40 (metastasis-free).
(B) Kaplan-Meier distant metastasis-free survival curves for 54 breast cancer patients, stratified based on miR-31 levels in their primary tumors. p value based on
a chi-square test.
(C) In situ hybridization for miR-31 (green) in patient-matched primary breast tumors and distant metastases (patient 1 = lung; 2 = pleura); DAPI counterstain (blue).
n = 8 fields.
(D) Immunohistochemical detection of ITGA5, RDX, and RhoA in patient-matched primary breast tumors and distant metastases (patient 1 = lung; 2 = pleura).
n = 8 fields.
Data are presented as mean ± SEM.in vitro assays might inadequately model the complexity of
metastasis; hence, in vivo manifestations of modeled behaviors
may require the concurrent action of multiple miR-31 effectors.
Also, not all steps of metastasis can be recapitulated in vitro.
Consistent with these notions, RhoA completely reversed
a number of miR-31-dependent defects in vitro, yet only partiallyrescued miR-31-imposed metastasis phenotypes in vivo. This
supports beliefs that miRNAs act via the pleiotropic regulation
of multiple effectors.
Our analyses rely on established human cell lines and xeno-
graft studies, approaches that cannot fully simulate clinical
carcinomas. For example, cell lines accumulate genetic changes(C) H&E stain of tissue adjacent to the indicated 231 primary mammary tumors 60 days after injection. Arrows indicate disseminated tumor cells in normal muscle
(a, c, e, g) and fat (b, d, f, h).
(D) Images of murine lungs to visualize GFP-labeled 231 cells 60 days after orthotopic injection (left). H&E stain of lungs from animals bearing the indicated tumors
(right); arrows indicate metastatic foci. n = 5.
(E) Images of murine lungs to detect GFP-labeled 231 cells 86 days after tail vein injection (left); arrows indicate micrometastatic lesions. Asterisks: p > 0.87 rela-
tive to vector + vector controls. n = 4, except for 2 weeks (n = 3).
Data are presented as mean ± SEM.Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc. 1043
in culture, whereas xenografts fail to recapitulate species-
specific interactions between tumor cells and their stroma.
However, the consistency of our results upon use of multiple
independent cell lines (including a single-cell-derived popula-
tion), the convergence of our gain- and loss-of-function findings,
and our correlative studies in human breast cancer patients and
murine mammary tumor cell lines argue against major confound-
ing influences stemming from our experimental models.
Collectively, the findings of the present study carry significant
implications regarding our understanding of the pathogenesis of
high-grade malignancies. Our data suggest that the loss of
a single gene product can facilitate the completion of multiple
distinct steps of the invasion-metastasis cascade; this pleio-
tropic action may help to explain how tumor cells can accumu-
late enough genetic and epigenetic aberrations over the course
of a human lifespan to overcome the numerous barriers that nor-
mally operate to prevent metastasis. Moreover, because distant
metastases are responsible for patient mortality in the vast
majority of human carcinomas, miR-31’s ability to impede
metastasis may prove to be clinically useful.
EXPERIMENTAL PROCEDURES
Cell Culture
MDA-MB-231 and MCF7-Ras cells were obtained from the ATCC and cultured
under standard conditions. HMEC and HME cells have been described (Ma
et al., 2007). SCP3 cells were obtained from J. Massague´ (Minn et al., 2005).
SUM-149 and -159 cells were provided by S. Ethier (Ma et al., 2007). D2 cells
have been described (Morris et al., 1993). 67NR, 168FARN, 4TO7, and 4T1
cells were obtained from F. Miller (Aslakson and Miller, 1992).
miRNA Detection
Total RNA, inclusive of the small RNA fraction, was extracted from cultured
cells with a mirVana miRNA Isolation Kit (Ambion). RT-PCR-based detection
of mature miR-31 and 5S rRNA was achieved with a mirVana miRNA Detection
Kit and gene-specific primers (Ambion).
miRNA In Situ Hybridization
miRNA expression was assessed from paraffin sections via a protocol adapted
from Silahtaroglu et al., (2007). In brief, after a 4 hr prehybridization, a 50 FITC-
labeled miRCURY LNA probe targeting miR-31 (Exiqon) was hybridized to
proteinase K-treated 10 mm sections at 55C for 12 hr. Slides were then incu-
bated with anti-FITC-HRP (PerkinElmer), and the resulting signal was intensi-
fied with the TSA Plus Fluorescein System (PerkinElmer).
Human Breast Tumors
Primary breast tumors, distant metastases, and normal breast tissue were
collected and processed in compliance with a protocol approved by the Brig-
ham and Women’s Hospital IRB. Fresh tissue was harvested from patients,
OCT-embedded, snap-frozen, and preserved at 80C. Recurrent cases
were primary tumors from patients that developed distant metastases. For
each recurrent case, two nonrecurrent cases were selected to control for
date of diagnosis, molecular subtype, lymph node status, and time of follow-
up. Total RNA was isolated from 35 mm sections via TRIzol extraction and
a mirVana miRNA Isolation Kit. To discern whether miR-31 levels correlate
with distant metastasis, primary tumors were classified as miR-31 positive
or negative. Tumors were considered miR-31 positive or negative if the
normalized expression of miR-31 resided in the top or bottom 30% of tumors
in this cohort, respectively. Similarly, tumors were classified as RhoA high or
low if their RhoA levels were in the top or bottom 30% of tumors examined.1044 Cell 137, 1032–1046, June 12, 2009 ª2009 Elsevier Inc.Invasion and Motility Assays
For invasion assays, 1.0 3 105 cells were seeded in a Matrigel-coated
chamber with 8.0 mm pores (BD Biosciences); for motility assays, 5.0 3 104
cells were plated atop uncoated membranes with 8.0 mm pores (BD Biosci-
ences). Cells were seeded in serum-free media and translocated toward
complete growth media for 20 hr. Fugene6 (Roche) was used to transfect cells
24 hr prior to plating. 200 nM miRIDIAN miRNA Inhibitors (Dharmacon) were
employed to transiently inhibit miR-31. SMARTpool siRNAs against Fzd3,
ITGA5, M-RIP, MMP16, RDX, or RhoA (Dharmacon) were provided at 100 nM.
Antisense oligonucleotides and siRNAs were transfected 48 hr prior to seeding
with Oligofectamine (Invitrogen).
Anoikis Assays
Anoikis resistance was evaluated by seeding 7.53 104 cells in ultralow attach-
ment plates (Corning). After 24 hr of anchorage-independent culture, cells
were resuspended in 0.4% trypan blue (Sigma) and cell viability was assessed.
Animal Studies
All research involving animals complied with protocols approved by the MIT
Committee on Animal Care. For spontaneous metastasis assays, age-
matched female NOD/SCID mice (propagated on-site) were bilaterally injected
into the mammary fat pad with the indicated number of tumor cells in 1:2 Ma-
trigel (BD Biosciences) plus normal growth media. For experimental metas-
tasis assays, age-matched female NOD/SCID mice were injected with 5.0 3
105 cells (resuspended in PBS) via the tail vein. Metastasis was quantified
with a fluorescent microscope within 3 hr of specimen isolation.
Luciferase Assays
5.0 3 104 cells were cotransfected with 50 ng of the indicated pIS1 Renilla
luciferase construct and 50 ng of a pIS0 firefly luciferase normalization control.
Lysates were collected 24 hr after transfection, and Renilla and firefly lucif-
erase activities were measured with a Dual-Luciferase Reporter System
(Promega).
Immunoblots
Lysates were resolved by electrophoresis, transferred to a PVDF membrane,
and probed with antibodies against b-actin (Santa Cruz), Fzd3 (Abcam),
ITGA5 (Santa Cruz), MMP16 (Abcam), RDX (Cell Signaling), or RhoA (Santa
Cruz).
miR-31 Target Signature
Expression profiling of 295 human breast tumors (van de Vijver et al., 2002)
was used to categorize tumors as miR-31 target signature positive or negative.
Tumors were considered target signature positive or negative if the normalized
expression of multiple of the six miR-31 targets herein identified resided in the
top or bottom 15% of tumors in this cohort, respectively.
Immunohistochemistry
Detection of Ki-67 (PharMingen), MECA-32 (U. of Iowa), ITGA5 (Santa Cruz),
RDX (Santa Cruz), or RhoA (Abcam) was performed on 5 mm paraffin sections
with the indicated antibodies, Vectastain Elite ABC kits (Vector), and
ImmPACT DAB Substrate (Vector).
Statistical Analyses
Data are presented as mean ± SEM. Unless otherwise noted, Student’s t test
was used for comparisons, with p < 0.05 considered significant.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 18
figures, 5 tables, and a video summary and can be found with this article online
at http://www.cell.com/cell/supplemental/S0092-8674(09)00390-0.
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